We Fight for the Rights of Personal Injury and Accident Victims
Our goal is to make sure you get the justice you deserve and are fully compensated for your harms and losses
Dupixent Cutaneous T-Cell Lymphoma (CTCL) Lawsuit
Have You or a Loved One Developed Cutaneous T-Cell Lymphoma After Starting Dupixent?
Dupixent CTCL Lawsuit Lawyer Tracy Paulsen is fighting for the rights of those who suffered from Eczema and now find themselves diagnosed with a rare lymphoma cancer called cutaneous T-cell lymphoma or CTCL. Rightful Legal is leading the charge against the manufacturers of this popular prescription Eczema medication for failing to warn consumers and doctors of this serious cancer risk side effect. The Eczema Lawsuit Lawyers at Rightful Legal are representing individuals who were diagnosed with CTCL after using Dupixent (the generic is known as dupilumab), particularly those being treated for atopic dermatitis or AD. If you or a loved one experienced a sudden or worsening onset of CTCL after starting Dupixent—especially without any prior lymphoma diagnosis—you may be eligible to file a lawsuit.
CTA – Diagnosed with Cutaneous T-Cell Lymphoma while Taking Dupixent?
Contact the Defective Drug Attorneys at Rightful Legal for a Confidential Case Review
New FDA Safety Signal Linking Dupixent Use with CTCL
On March 31, 2025, the U.S. Food and Drug Administration (FDA) issued a Newly Identified Safety Signal (NISS) after analyzing adverse event data from the final quarter of 2024. This safety alert specifically noted a concerning link between Dupixent and CTCL—a rare and aggressive type of non-Hodgkin’s lymphoma that primarily affects the skin.
As of now, Dupixent’s label includes no warning of this potential cancer risk. Regulatory review is ongoing, but early legal investigation has begun into whether manufacturers Sanofi and Regeneron Pharmaceuticals failed to adequately warn patients and doctors of the risk of CTCL development or progression.
What Is Dupixent?
Dupixent is a prescription drug developed by Regeneron and Sanofi Genzyme. It was approved by the FDA in 2017 for the treatment of the following conditions:
– Moderate to severe Atopic Dermatitis, more commonly referred to as Eczema
– Asthma
– Chronic rhinosinusitis with nasal polyps
– Eosinophilic esophagitis
– Prurigo nodularis
As both an IL-4 and IL-13 pathway inhibitor, Dupixent works by suppressing parts of the immune system responsible for inflammatory responses. It is widely prescribed, especially for patients who have not responded to topical steroids or other treatments to help with the painful and difficult symptoms associated with severe Eczema.
Though the drug is intended to only suppress inflammatory responses particular to AD, Dupixent’s immunomodulating mechanism may unintentionally interfere with the body’s ability to detect or suppress cancerous T-cells—raising significant concerns about its role in CTCL development in patients using Dupixent.
What is Cutaneous T-Cell Lymphoma or CTCL
CTCL is a group of rare cancers that originate in the skin’s T-lymphocytes (a type of white blood cell). Unlike most lymphomas that begin in lymph nodes, CTCL starts in the skin and may slowly spread throughout the body.
There are several subtypes of CTCL, with the most common being:
- Mycosis Fungoides – the most prevalent form of CTCL, often mistaken for eczema or psoriasis in early stages.
- Sézary Syndrome – a more aggressive leukemic form with widespread skin redness and abnormal T-cells in the blood.
Symptoms of CTCL may include:
- Persistent skin rashes
- Dry, scaly patches
- Lumps or tumors on the skin
- Itching or burning sensations
- Swollen lymph nodes
One very important fact to note, is that CTCL is often misdiagnosed as atopic dermatitis or other skin conditions. This means that patients taking Dupixent for eczema may actually have undiagnosed lymphoma that progresses or becomes unmasked after starting the medication.
The Scientific Support Linking Dupixent to CTCL
CTCL is typically a very rare condition. Scientific literature and pharmacological data, however, have increasingly reported cases of new or accelerated CTCL development following Dupixent initiation. This does not appear to be a coincidence.
A few significant studies to note include:
- A 2020 study published in the Journal of the American Academy of Dermatology documented cases where patients developed CTCL after being treated with Dupixent for presumed atopic dermatitis.
- A 2022 case series in JAAD Case Reports described multiple instances where CTCL emerged or rapidly progressed after patients began Dupixent therapy.
- Internal analysis by the FDA’s Adverse Event Reporting System (FAERS) has now confirmed sufficient signal strength to warrant the March 2025 safety alert.
Taken together, the data suggest a serious risk that was not previously disclosed in Dupixent’s warning label to consumers and the medical community, which serves as potential grounds for litigation against Sanofi Genzyme and Regeneron.
Why are Dupixent Manufacturers Sanofi Genzyme and Regeneron Potentially Liable for a Failure to Warn?
In prescription drug cases, a “failure to warn” claim arises when a manufacturer knows, or should reasonably know, of a significant health risk but does not adequately disclose it to prescribing doctors and patients. Under U.S. product liability law, pharmaceutical companies have a duty to provide clear, complete, and timely warnings about all known or reasonably foreseeable side effects so that patients can make informed decisions about their care. In the case of Dupixent, the recent FDA safety signal and published medical reports suggest a potential association between the drug and cutaneous T-cell lymphoma. If Sanofi Genzyme and Regeneron failed to update their product labeling, issue safety alerts, or otherwise inform the medical community about this potential cancer risk, they may be legally liable for harm caused to patients who developed CTCL after taking Dupixent.
Strict deadlines can limit how long you have to bring a claim, it is important to contact the experienced product liability lawyers at Rightful Legal today. Our team understands the complexities of pharmaceutical litigation and can take immediate steps to protect your rights and pursue the maximum compensation you deserve.
Rightful Legal is Focusing on Two Key Injury Categories for the Dupixent Lawsuit
1. New Onset CTCL Following the Use of Dupixent: This category is where the patient had no known prior diagnosis of CTCL but developed the condition after beginning Dupixent treatment.
2. Unmasking or Progression of Undiagnosed CTCL: This category is where patients may have had early CTCL that was misdiagnosed as eczema or Atopic Dermitis and Dupixent made the CTCL worse.
Who May Be Eligible to File a Dupixent CTCL Lawsuit?
You may be eligible to file a lawsuit against the Dupixent Manufacturers if you or a loved one:
– Used Dupixent for the treatment of eczema, atopic dermitis or another approved condition
– Were diagnosed with CTCL after starting Dupixent
– Had no prior CTCL diagnosis or experienced rapid worsening of undiagnosed or misdiagnosed CTCL, and
– Were not warned about the potential cancer risk
CTA – Treated Eczema with Dupixent only to be Diagnosed with Cancer?
Contact Attorney Tracy Paulsen Today for a Free Case Evaluation
Why The Dupixent Cancer Litigation Matters
At Rightful Legal, our mission is simple yet powerful: to stand up for individuals and families harmed by corporate negligence and fight relentlessly for the justice they deserve. Pharmaceutical companies have both a legal and moral obligation to warn patients and doctors about known or foreseeable risks. When a drug like Dupixent is marketed to vulnerable patients—including children, seniors, and those with weakened immune systems—failing to disclose a potential cancer risk is not just negligent, it’s dangerous.
Attorney Tracy Paulsen has dedicated her career to holding powerful corporations accountable when they put profits ahead of patient safety. With over 15 years of experience in product liability cases, she and her team have earned a reputation for winning results and delivering compassionate, personalized advocacy.
Speak With Attorney Tracy Paulsen About Your Dupixent Cancer Claim Today
The FDA is still investigating the potential link between Dupixent and cutaneous T-cell lymphoma, and the drug’s manufacturers have yet to update their warnings. You should not have to wait for them to act before protecting your health and your legal rights.
If you believe Dupixent may have caused or worsened CTCL in yourself or a loved one, contact Attorney Tracy Paulsen at Rightful Legal today. Tracy will personally ensure your case receives the thorough attention it deserves, guiding you through every step of the process and fighting for the maximum compensation available. Our consultations are free, confidential, and without obligation.
Call Rightful Legal now at 617-821-5856 or fill out our secure online form. Time is critical — strict legal deadlines may apply in your state, and your opportunity to seek justice could be lost if you wait.
